---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-104272"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:11:27.595702+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics enrolls 8th patient in SBMA trial, triggering 276,652 share issuance to AnnJi

## Summary
- Enrolled eighth patient in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA).
- Issued 276,652 shares of common stock to AnnJi as Second Tranche Shares under license agreement.
- Trial is 12-week, multicenter, randomized, double-blind, targeting ~24 patients; primary endpoint safety/tolerability.
- AJ201 activates Nrf1/Nrf2 and enhances androgen receptor degradation; previously paid $3M cash and 831,618 shares.

## SEC filing metadata
- accession: 0001104659-23-104272
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/0001104659-23-104272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923104272/tm2327078d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-104272
- JSON: https://secwatch.observer/filing/0001104659-23-104272.json
- Plain text: https://secwatch.observer/filing/0001104659-23-104272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.